Pharmaceuticals

Gastroesophageal Reflux Disease Therapeutics Market Expansion to $7.74 Billion by 2029: Key Drivers and Trends

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the gastroesophageal reflux disease therapeutics market from 2025–2034 with trusted insights from The Business Research Company

What Is The Base Market Size For The Gastroesophageal Reflux Disease Therapeutics Market Today And What Will It Reach By 2029?

The size of the gastroesophageal reflux disease therapeutics market has seen consistent growth over recent years. This market is projected to expand from $5.93 billion in 2024 to $6.08 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 2.5%. Factors contributing to its historical expansion include evolving lifestyles and dietary patterns, an expanding aging population, enhanced awareness and diagnostic capabilities, prevalent stressful lifestyles, and an increase in obesity rates.

The gastroesophageal reflux disease therapeutics market size is projected to experience robust growth in the upcoming years. It is expected to expand to $7.74 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.2%. The anticipated growth during the forecast period can be ascribed to an increasing demand for novel therapies, a rising geriatric population, the adoption of personalized medicine approaches, a focus on non-pharmacological interventions, and the emergence of biologics and other innovative treatments. Significant trends expected in the forecast period include the rise of alternative therapies and mind-body practices, expanded research into gut health, the advent of patient-centric care models, targeted marketing for GERD awareness, and the integration of digital health tools.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp

What Factors Are Boosting The Gastroesophageal Reflux Disease Therapeutics Market?

The increasing occurrence of gastroesophageal reflux disease is projected to fuel the expansion of the gastroesophageal reflux disease therapeutics market. Gastroesophageal reflux disease is a persistent ailment where stomach acid flows back into the esophagus, leading to symptoms like heartburn, regurgitation, and various complications. Medications for gastroesophageal reflux disease (GERD) aid in alleviating and controlling acid reflux symptoms by balancing gut pH, managing inflammation, and enhancing esophageal performance. For example, data from September 2022, reported in an article by WebMed, a US-based online health information publisher, indicates that over 60 million American adults experience heartburn monthly, with more than 15 million enduring it daily. Additionally, statistics from July 2022, provided by the National Library of Medicine, a US-based federal medical library, highlight that GERD is among the most frequently diagnosed digestive conditions in the United States, affecting 20% of the population. This contributes to substantial economic costs through direct and indirect spending and negatively impacts overall quality of life. Consequently, the widespread presence of gastroesophageal reflux disease is anticipated to stimulate the expansion of the gastroesophageal reflux disease therapeutics market.

How Is The Gastroesophageal Reflux Disease Therapeutics Market Categorized By Application, Type, And Region?

The gastroesophageal reflux disease therapeutics market covered in this report is segmented –

1) By Type: Branded, Generic

2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class

3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets

4) By Application: Crohn’s Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis

Subsegments:

1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents

2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents

How Are Technological Trends Affecting The Gastroesophageal Reflux Disease Therapeutics Market Growth?

Product innovations represent a significant trend gaining traction within the gastroesophageal reflux disease therapeutics market. Leading companies operating in the gastroesophageal reflux disease therapeutics market are channeling their efforts into developing advanced medications to secure their position in the industry. For instance, in November 2023, Phathom Pharmaceuticals, a US-based biopharmaceutical company, introduced VOQUEZNA (vonoprazan), a potassium-competitive acid blocker, which was approved for the healing and maintenance of all grades of erosive esophagitis, and also for relieving heartburn associated with both erosive and non-erosive GERD. Clinical trials revealed notable outcomes, showing a healing rate of 93% in patients treated with the 20 mg dosage, in comparison to 85% for the standard proton pump inhibitor (PPI) lansoprazole.

Who Are The Global Leaders Steering The Gastroesophageal Reflux Disease Therapeutics Market Forward?

Major companies operating in the gastroesophageal reflux disease therapeutics market include Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Gastroesophageal Reflux Disease Therapeutics Market?

North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=12058&type=smp

Browse Through More Reports Similar to the Global Gastroesophageal Reflux Disease Therapeutics Market 2025, By The Business Research Company

Real Time Location Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/real-time-location-systems-global-market-report

Rail Asset Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rail-asset-management-global-market-report

Wireless Intercom Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wireless-intercom-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795